PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|January 2, 2020
- Pharmaceutical Technology-01-02-2020
- Volume 44
- Issue 1
Plastic Mixing Systems
Terracon Corporation unveiled a line of turnkey, magnetic-drive plastic mixing systems for applications within pharmaceutical markets.
Terracon Corporation unveiled a line of turnkey, magnetic-drive plastic mixing systems for applications within pharmaceutical markets. The systems are fully customizable and formulated for precise development and production processes.
Designed with low shear to protect pharmaceutical products, the system’s raised Zero-g mix head hovers vertically on a magnetic cushion, eliminating mechanical seals, acting as a shock absorber for the mixer to reduce the risk of particle shedding, and providing the highest level of aseptic design. The mixer’s polypropylene construction and mix head are USP Class VI-, FDA-, and GMP-compliant and provide 100% non-metallic surface contact. The mixing systems are available in 50L, 400L, and 1000L sizes and are now available for order. The systems are available in 50L, 400L, and 1000L sizes.
Articles in this issue
over 6 years ago
Human-Centered Work: How Pharma Can Move to a Blame-Free Cultureover 6 years ago
Public Opinion: Can Pharma Chart a New Course?almost 7 years ago
Pharma Regulation to be Shaped by Pricing and Production Issuesalmost 7 years ago
Can Policy Keep Pace with Science and Discoveries?almost 7 years ago
Production, Packaging, and Inspectionalmost 7 years ago
ReNu Single-Use Technology Cartridge Assembliesalmost 7 years ago
Sanitary Tumble Blenderalmost 7 years ago
US Maintains Lead in Drug Development Despite Fewer Approvals in 2019almost 7 years ago
Choices for Climbing the Career Ladderalmost 7 years ago
Optimizing Machine HealthRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
3
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
4
What the Olanzapine Depot Approval Means for CMC Teams
5